, Volume 38, Issue 2, pp 527–533 | Cite as

Protective Effects of Embelin on Myocardial Ischemia–Reperfusion Injury Following Cardiac Arrest in a Rabbit Model

  • Zhi-Gang Zhao
  • Zhong-Zhi Tang
  • Wen-Kai Zhang
  • Jian-Guo Li


Embelin has been used to treat fever and inflammatory diseases for thousands of years. Although reports indicate that embelin has antiinflammatory effects, its effects on myocardial injury following cardiac arrest (CA) have not been previously explored. In this study, we aim to investigate the protective effects of embelin on myocardial ischemia–reperfusion injury (IRI) following CA in a rabbit model. Pro-inflammatory (TNF-α, IL-1β, and IL-6) cytokines, cardiac troponin I (cTnI), necrosis ratio, apoptotic index (AI), hemodynamics, nuclear factor-kappa B (NF-κB) p65, and histological damage have been measured or evaluated. Embelin reverts TNF-α, IL-1β, and IL-6 to basal levels and reduces the serum level of cTnI, the necrosis ratio, the AI, and the expression of NF-κB p65. Meanwhile, it improves the hemodynamics and myocardial function. Moreover, embelin-treated groups also showed improved myocardial morphology. Our results indicate that embelin may protect the heart against myocardial IRI following CA via its antiinflammatory abilities.


embelin antiinflammatory effects cardiac arrest myocardial ischemia–reperfusion injury 



We would like to thank the Center for Animal Experiment for the assistance in animal study.

Conflict of Interest

The authors declare no conflict of interest.


  1. 1.
    Geocadin, R.G., M.A. Peberdy, and R.M. Lazar. 2012. Poor survival after cardiac arrest resuscitation: a self-fulfilling prophecy or biologic destiny? Crit Care Med 40: 979–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Chalkias, A., and T. Xanthos. 2012. Pathophysiology and pathogenesis of post-resuscitation myocardial stunning. Heart Fail Rev 17: 117–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Adrie, C., M. Adib-Conquy, I. Laurent, et al. 2002. Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. Circulation 106: 562–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen, Z., Z. Wu, C. Huang, et al. 2013. Effect of lipoxin A4 on myocardial ischemia reperfusion injury following cardiac arrest in a rabbit model. Inflammation 36: 468–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Kapoor, V.K., A.S. Chawla, M. Kumar, et al. 1983. Anti-inflammatory agent in Indian Laboratories. Indian Drugs 30: 481–488.Google Scholar
  6. 6.
    Joshi, R., J.P. Kamat, and T. Mukherjee. 2007. Free radical scavenging reactions and antioxidant activity of embelin: biochemical and pulse radiolytic studies. Chem Biol Interact 167: 125–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Singh, D., R. Singh, P. Singh, et al. 2009. Effects of embelin on lipid peroxidation and free radical scavenging activity against liver damage in rats. Basic Clin Pharmacol Toxicol 105: 243–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Chitra, M., S. Devi, and E. Sukumar. 2003. Antibacterial activity of embelin. Fitoterapia 74: 401–403.PubMedCrossRefGoogle Scholar
  9. 9.
    Bhandari, U., and M.N. Ansari. 2009. Ameliorative effect of an ethanol extract of Embelia ribes fruits on isoproterenol-induced cardiotoxicity in diabetic rats. Pharm Biol 47: 669–674.CrossRefGoogle Scholar
  10. 10.
    Chitra, M., E. Sukumar, V. Suja, et al. 1994. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy 40: 109–113.PubMedCrossRefGoogle Scholar
  11. 11.
    Thippeswamy, B.S1., S. Mahendran, M.I. Biradar, et al. 2011. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur J Pharmacol 654: 100–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Kumar, G.K1., R. Dhamotharan, N.M. Kulkarni, et al. 2011. Embelin ameliorates dextran sodium sulfate-induced colitis in mice. Int Immunopharmacol 11: 724–31.CrossRefGoogle Scholar
  13. 13.
    Ahn, K.S., G. Sethi, and B.B. Aggarwal. 2007. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol 71: 209–19.PubMedCrossRefGoogle Scholar
  14. 14.
    Chen, M.H., L. Xie, T.W. Liu, et al. 2007. Epinephrine, but not vasopressin, improves survival rates in an adult rabbit model of asphyxia cardiac arrest. Am J Emerg Med 25: 509–14.PubMedCrossRefGoogle Scholar
  15. 15.
    Gross, G.J., and J.A. Auchampach. 2007. Reperfusion injury: does it exist? J Mol Cell Cardiol 42: 12–8.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Jordan, J.E., Z. Zhao, and J. Vinten-Johansen. 1999. The role of neutrophils in myocardial ischemia–reperfusion injury. Cardiovasc Res 43: 860–78.PubMedCrossRefGoogle Scholar
  17. 17.
    Adrie, C., I. Laurent, M. Monchi, et al. 2004. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care 10: 208–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Laurent, I., M. Monchi, J.D. Chiche, et al. 2002. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. J Am Coll Cardiol 40: 2110–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Nolan, J.P., R.W. Neumar, C. Adrie, et al. 2010. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication: a scientific statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke (Part II). Int Emerg Nurs 18: 8–28.PubMedCrossRefGoogle Scholar
  20. 20.
    Ruiz-Bailén, M., E. Aguayo de Hoyos, S. Ruiz-Navarro, et al. 2005. Reversible myocardial dysfunction after cardiopulmonary resuscitation. Resuscitation 66: 175–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Vinten-Johansen, J1., R. Jiang, J.G. Reeves, et al. 2007. Inflammation, proinflammatory mediators and myocardial ischemia-reperfusion Injury. Hematol Oncol Clin North Am 21: 123–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Kalyan Kumar, G., R. Dhamotharan, N.M. Kulkarni, et al. 2011. Embelin reduces cutaneous TNF-alpha level and ameliorates skin edema in acute and chronic model of skin inflammation in mice. Eur J Pharmacol 662: 63–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Park, S.Y., S.L. Lim, H.J. Jang, et al. 2013. Embelin induces apoptosis in human glioma cells through inactivating NF-kappaB. J Pharmacol Sci 121: 192–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Aggarwal, B.B. 2004. Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Moss, N.C., W.E. Stansfield, M.S. Willis, et al. 2007. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 293: H2248–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Gordon, J.W., J.A. Shaw, and L.A. Kirshenbaum. 2011. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 108: 1122–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Yang, J., H. Jiang, J. Yang, et al. 2009. Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 330: 39–46.PubMedCrossRefGoogle Scholar
  28. 28.
    Zeng, M., H. Yan, Y. Chen, et al. 2012. Suppression of NF-kappaB reduces myocardial no-reflow. PLoS One 7: e47306.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Ni, H., W. Zhao, X. Kong, et al. 2014. NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis. PLoS One 9: e95846.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Lewis, J1., E. Burstein, S.B. Reffey, et al. 2004. Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. J Biol Chem 279: 9023–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Zhi-Gang Zhao
    • 1
    • 2
  • Zhong-Zhi Tang
    • 2
  • Wen-Kai Zhang
    • 2
  • Jian-Guo Li
    • 1
  1. 1.Intensive Care UnitZhongnan Hospital of Wuhan UniversityWuhanChina
  2. 2.Emergency DepartmentWuhan General Hospital of Guangzhou Military CommandWuhanChina

Personalised recommendations